Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine |
| |
Authors: | Elizabeth A Vasievich Weihsu Chen Leaf Huang |
| |
Institution: | (1) Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Kerr Hall, Campus Box 7571, Chapel Hill, NC 27599, USA;(2) Ontario Institute for Cancer Research, Toronto, Canada; |
| |
Abstract: | Commercially available DOTAP is a racemic mixture of two enantiomers. The adjuvanticity of each isomer was examined using
a peptide/lipid complex as a therapeutic vaccine in an established murine cervical cancer model. This simple vaccine consists
of a cationic lipid (DOTAP) and a major histocompatibility complex (MHC) class I–restricted epitope of the Human Papillomavirus
(HPV) 16 protein E7. Dose-dependent tumor regression experiments have been completed for racemic DOTAP/E7, (R)-DOTAP/E7 and
(S)-DOTAP/E7. Tumor-bearing mice treated with (R)-DOTAP/E7 complexes have shown tumor regression in a dose-dependent manner
comparable to those mice treated with a racemic DOTAP with E7 peptide. These data are supported by IFN-γ production by CD8+ splenocytes, in vivo cytotoxic T-lymphocytes (CTL) response, CD8+ tumor-infiltrating lymphocytes (TIL), and IFN-γ production by CD8+ TIL in (R)-DOTAP/E7-vaccinated mice. When (S)-DOTAP/E7 is delivered, tumor progression is delayed. While IFN-γ production
is absent from CD8+ splenocytes in mice vaccinated with (S)-DOTAP/E7, IFN-γ production by CD8+ TIL is present, supporting our hypothesis that (S)-DOTAP has limited activity. Activation of bone marrow-derived dendritic
cells by the enantiomeric formulations has also been evaluated, as well as cytokine production and toxicity with no considerable
differences between the groups. The results show the DOTAP enantiomers act differently as adjuvants in vivo, with (R)-DOTAP
being more effective at stimulating a CD8+ anti-tumor response. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|